Drug Profile
Research programme: pain therapeutics - Interprotein Corporation/RaQualia Pharma
Alternative Names: PPI inhibitors - Interprotein/RaQualia Pharma; Protein-protein interaction inhibitors - Interprotein/RaQualia PharmaLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Interprotein Corporation; RaQualia Pharma
- Class Analgesics; Small molecules
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for research development in Pain in Japan
- 01 Feb 2021 Early research is underway for Pain (RaQualia Pharma pipeline, February 2021)
- 16 Jul 2016 No recent reports of development identified for research development in Pain in Japan